

HACKETTSTOWN REGIONAL MEDICAL CENTER

MRSA (Methicillin Resistant staphylococcus Aureus) SCREENING

Effective Date:	January 2008	Policy No:	IC 0022
Cross Referenced:		Origin:	Infection Control
Reviewed Date:	September 2010	Authority:	Edward McManus, M.D.
Revised Date:		Page:	1 of 2

PURPOSE: Compliance with New Jersey Act concerning the prevention of health care facility-acquired infections and supplementing Title 26.

SUPPORTING DATA:

Senate, No. 2580; State of New Jersey; 212th legislature; Assembly, No. 4179 State of New Jersey. C.26:2H-12.35 – C.26:2H-12.38. Aug. 2, 2007; Management of Multidrug-Resistant Organisms in Healthcare Settings 2006 CDC

PROCEDURE:

1. All patients being admitted to the ICU will be screened for MRSA.
2. Emergency Dept. Nursing will obtain the MRSA Screening nasal swab in the ED following the Standing Order for MRSA Screening form.
3. Patients to be screened for MRSA:
 - a. All admits from the ED to ICU
 - b. Direct admits to the ICU
 - c. Transfers to ICU from other units: on the admitting unit.
 - d. Transfers or discharges from ICU if they have been an inpatient for 72 hours or more.
4. The screening cultures will be done in accordance with HRMC laboratory policy for specimen collection of nares cultures for MRSA SCREEN.
5. MRSA positive test results are a critical value and will be reported by St. Clare's laboratory by telephone to the patients unit. The RN receiving the communication must document the result.
6. Patients who test positive for MRSA will be placed on CONTACT PRECAUTIONS in accordance with current IC policy.
7. Colonization or infection of the patient will be determined by the physician.
8. Decision to decolonize a positive colonized patient will be at the discretion of the attending physician. If the physician elects to decolonize they will be advised to follow the decolonization protocol set forth by the Infectious Disease physician in charge of Infection Control at HRMC.

Doxycycline 100mg PO BID	Rifampin 300mg PO BID
Bactroban nasally TID	Hibiclens wash daily

HACKETTSTOWN REGIONAL MEDICAL CENTER

MRSA (Methicillin Resistant staphylococcus Aureus) SCREENING

Effective Date: January 2008

Policy No: IC 0022

Cross Referenced:

Origin: Infection Control

Reviewed Date: September 2010

Authority: Edward McManus, M.D.

Revised Date:

Page: 2 of 2

1. If allergy doxycycline may be substituted with Bactram DS BID or Zyvox 600 mg BID.
 2. If any questions or concerns physicians may contact I D services.
9. Patients who are treated for active infection of MRSA can be retested in accordance with IC policy IC 006.